Home » Stocks » AXSM

Axsome Therapeutics, Inc. (AXSM)

Stock Price: $69.31 USD 1.96 (2.90%)
Updated Jun 21, 2021 12:03 PM EDT - Market open
Market Cap 2.53B
Revenue (ttm) n/a
Net Income (ttm) -99.68M
Shares Out 37.43M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $69.31
Previous Close $67.35
Change ($) 1.96
Change (%) 2.90%
Day's Open 66.93
Day's Range 65.85 - 69.74
Day's Volume 174,904
52-Week Range 50.05 - 90.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 13% rise over the last twenty-one trading sess...

2 hours ago - Forbes

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

5 days ago - Zacks Investment Research

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is cu...

6 days ago - Benzinga

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.

Other stocks mentioned: BBIO
2 weeks ago - The Motley Fool

A sharp pivot away from growth has given Wall Street a much different perspective on what constitutes today's best Nasdaq stocks. Take a look.

Other stocks mentioned: AMZN, BLDR, GLPI, GOOG, GOOGL, HCAT, JD ...
1 month ago - Kiplinger

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.

1 month ago - Zacks Investment Research

Company to host conference call today at 8:00 AM Eastern

1 month ago - GlobeNewsWire

Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by ra...

1 month ago - GlobeNewsWire

The stocks of Novavax and Axsome Therapeutics are soaring. Here's why.

Other stocks mentioned: NVAX
1 month ago - The Motley Fool

Their stocks have collapsed. But they could still be huge winners.

Other stocks mentioned: FREQ, TRIL
1 month ago - The Motley Fool

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other stocks mentioned: QURE, VYGR, CRSP, RVPH
1 month ago - Benzinga

The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.

1 month ago - The Motley Fool

The first new treatment for millions of Americans with major depressive disorder could become available this summer.

1 month ago - The Motley Fool

Axsome Therapeutics snagged a speedy review from the Food and Drug Administration for its depression treatment, known as AXS-05, on Monday, leading Axsome stock to gap higher. The post Axsome Stock Jump...

1 month ago - Investors Business Daily

AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now.

1 month ago - InvestorPlace

Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD). The target action date is set at August 22.

1 month ago - Benzinga

FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021

1 month ago - GlobeNewsWire

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Other stocks mentioned: AVXL, BIIB, JAZZ, SAVA
1 month ago - Zacks Investment Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

The upstart biotech is filing two new drug applications in 2021, and has several more on the way.

3 months ago - The Motley Fool

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

3 months ago - Zacks Investment Research

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...

4 months ago - GlobeNewsWire

This company presents much more attractive prospects than the cryptocurrency.

4 months ago - The Motley Fool

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Other stocks mentioned: AVXL, HOLX, MRNA, NVAX, SAVA, VIVO, VXRT
4 months ago - Zacks Investment Research

While it's already made some people rich, Axsome Therapeutics is just getting started.

4 months ago - The Motley Fool

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Other stocks mentioned: JNJ, NVAX
5 months ago - The Dog of Wall Street

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

5 months ago - Zacks Investment Research

ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation

5 months ago - GlobeNewsWire

The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout of...

5 months ago - Seeking Alpha

68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4

6 months ago - GlobeNewsWire

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment

6 months ago - GlobeNewsWire

R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months

6 months ago - GlobeNewsWire

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07.

7 months ago - Zacks Investment Research

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

NEW YORK & PLEASANTON, Calif.--(BUSINESS WIRE)-- #digitalengagement--Axsome and Veeva announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform.

Other stocks mentioned: VEEV
7 months ago - Business Wire

NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...

7 months ago - GlobeNewsWire

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time

7 months ago - GlobeNewsWire

Axsome has an excellent pipeline of late stage CNS candidates. The total market opportunity of all 4 assets is nearly $8bn.

7 months ago - Seeking Alpha

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared fir...

Other stocks mentioned: MDGL, NKLA, TLRY
8 months ago - InvestorPlace

The Recent Sell-Off In Axsome Creates A Good Opportunity

8 months ago - Seeking Alpha

Today, we revisit Axsome Therapeutics for an in-depth analysis.

8 months ago - Seeking Alpha

An analyst doesn't think very highly of Axsome's prospects.

8 months ago - The Motley Fool

Non-dilutive committed capital extends cash runway into at least 2024

8 months ago - GlobeNewsWire

        S ignificantly faster time to pain relief as compared to rizatriptan (p

8 months ago - GlobeNewsWire

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

8 months ago - Zacks Investment Research

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 19, 2015
CEO
Herriot Tabuteau
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
AXSM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 140.21, which is an increase of 102.31% from the latest price.

Price Target
$140.21
(102.31% upside)
Analyst Consensus: Strong Buy